2017 was our biggest event to date and it was a real inflection point for the industry. After several approvals in the US, the Biosimilar Industry is now finally ready to fulfil its promise and become a multi-billion-dollar business providing real benefits to healthcare. On the back of these approvals it is becoming a far more crowded and competitive landscape but getting a biosimilar to the patient still presents a number of challenges that the World Biosimilar Congress will look to address.
Across the two days, industry and thought-leading speakers from across the globe will come together to network and discuss the key issues on biosimilar drug development, commercialisation, market access and healthcare uptake.
As part of the Festival of Biologics, the World Biosimilar Congress will be co-located with European Antibody Congress, World Immunotherapy Congress and HPAPI World Congress.
Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
We look forward to welcoming you to Basel.